Form 4: TriSalus Life Sciences Executive Sells Shares

Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences, Inc., reported a sale of 543 common shares on May 15, 2026, for tax withholding purposes.

Summary

• Richard Marshak, Chief Commercial Officer at TriSalus Life Sciences, Inc. (TLSI), reported a transaction on May 15, 2026.
• Marshak sold 543 shares of common stock at a price of $2.67 per share.
• This sale was to satisfy tax withholding obligations related to the vesting of restricted stock units.
• The transaction is not considered a discretionary sale by the reporting person.
• Following this transaction, Marshak beneficially owns 125,101 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported stock sale is explicitly stated to be for tax withholding purposes and not a discretionary decision by the executive.

Negatives

• A sale of company stock by a key executive, even if for tax purposes, can sometimes be perceived negatively by the market.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it is a statement of changes in beneficial ownership.

Management Comments

• The transaction does not represent a discretionary sale by the Reporting Person.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors regarding their stock transactions. While this specific transaction is for tax withholding and not a discretionary sale, any stock sale by management can be a point of observation for investors.

Stakeholder Impact

• Shareholders: The sale is for tax withholding, so it does not directly indicate a lack of confidence in the company's future by the executive. However, any stock sale can be a point of scrutiny.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, Form 4, Insider Trading, Stock Sale, Executive Compensation, Restricted Stock Units, Tax Withholding